Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
    Journal Article

    Hobbs, G. S.; Hanasoge Somasundara, A. V.; Kleppe, M.; Litvin, R.; Arcila, M.; Ahn, J.; McKenney, A. S.; Knapp, K.; Ptashkin, R.; Weinstein, H.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
    Journal Article

    Stein, E. M.
    Future Oncology (2018)

    Fulltext@MSK | Save
  • Digging deeper in relapsed acute lymphoblastic leukemia: Impact of MRD status on outcome in second remission
    Journal Article

    Geyer, M. B.; Tallman, M. S.
    Leukemia and Lymphoma (2018)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR) T cells genetically engineered to deliver IL-12 to the tumor microenvironment in ovarian cancer
    Meeting Abstract

    Yeku, O. O.; Purdon, T.; Spriggs, D. R.; Brentjens, R. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Treatment patterns and characteristics of acute promyelocytic leukemia (APL) patients receiving arsenic trioxide (ATO) therapy in a real-world setting
    Meeting Abstract

    Tang, B.; Gabriel, S.; Zhou, J.; Pathak, A. K.; Irwin, D.; Riehle, E.; Lo-Coco, F.; Tallman, M. S.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study
    Meeting Abstract

    Stein, E. M.; Dinardo, C. D.; Pollyea, D. A.; Fathi, A. T.; Roboz, G. J.; Altman, J. K.; Stone, R. M.; Flinn, I.; Kantarjian, H. M.; Collins, R.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML
    Meeting Abstract

    Stone, R. M.; Collins, R.; Tallman, M. S.; Walter, R. B.; Karanes, C.; Patel, P. A.; Vusirikala, M.; Coombs, C. C.; Olson, G.; Jain, V. K.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • H3B-8800-G0001-101: A first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies
    Meeting Abstract

    Steensma, D. P.; Maris, M. B.; Yang, J.; Donnellan, W. B.; Brunner, A. M.; McMasters, M.; Greenberg, P.; Komrokji, R. S.; Klimek, V. M.; Goldberg, J. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells
    Meeting Abstract

    Santomasso, B.; Park, J. H.; Riviere, I.; Mead, E.; Halton, E.; Diamonte, C.; Purdon, T.; Senechal, B.; Li, D.; Sadelain, M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
    Meeting Abstract

    Ruppert, A. S.; Byrd, J. C.; Heerema, N. A.; Smith, M. R.; Godwin, J. E.; Couban, S.; Fehniger, T. A.; Thirman, M.; Halvorson, A. E.; Tallman, M. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save